UC Davis Veterinary Clinical Trials

Assessing a New Drug to Treat Heart Failure in Dogs with Myxomatous Mitral Valve Disease

Please bring your dog with congestive heart failure directly to the UC Davis VMTH Emergency Room!

Myxomatous mitral valve disease is the most common cardiac disease and the leading cause of congestive heart failure in dogs. Reducing blood pressure is one strategy to help manage these patients. By reducing blood pressure, the heart can move blood forward more effectively, reducing fluid accumulation in the lungs that can result from this condition. However, available medications for this health emergency are extremely limited and currently available drugs often have extreme price volatility, low availability or unwanted side effects. Researchers will conduct a small clinical trial to evaluate the use of a new drug clevidipine to reduce blood pressure in client-owned dogs admitted to hospital. Finding a safe, affordable alternative drug that is readily available may help improve survival of critically ill canine patients requiring urgent care for heart failure.

Drug - Treatment

VACCS: Vaccination Against Canine Cancer Study

Help us prevent cancer in dogs with a new vaccine!

Cancer is the leading cause of death in dogs, accounting for approximately 30% of all deaths. Certain breeds have much higher likelihoods of cancer than others. “Tumor antigens” are proteins that can be recognized by the immune system as foreign and result in the attack of tumors by the immune system. Researchers have identified a series of new tumor antigens that appear to be produced in multiple types of cancer very early in tumor development and are produced in cancers from many species (humans, dogs and mice). Vaccination of mice with these antigens can delay or prevent multiple types of cancer without side effects. The purpose of this study is to determine whether vaccination with these novel tumor antigens is capable of reducing the likelihood of cancer in dogs.

Preventative vaccine study
Loading